CERo Therapeutics Holdings, Inc. Common Stock Asset Resilience Ratio
CERo Therapeutics Holdings, Inc. Common Stock asset resilience ratio. CERo Therapeutics Holdings, Inc. Common Stock (CERO) has an Asset Resilience Ratio of 8.06% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CERO cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of CERo Therapeutics Holdings, Inc. Common Stock (None–None)
Asset resilience ratio of CERo Therapeutics Holdings, Inc. Common Stock from None to None. This chart shows how CERo Therapeutics Holdings, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read CERo Therapeutics Holdings, Inc. Common (CERO) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down CERo Therapeutics Holdings, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CERo Therapeutics Holdings, Inc. Common (CERO) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $500.00K | 8.06% |
| Total Liquid Assets | $500.00K | 8.06% |
Asset Resilience Insights
- Limited Liquidity: CERo Therapeutics Holdings, Inc. Common Stock maintains only 8.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CERo Therapeutics Holdings, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare CERo Therapeutics Holdings, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Disc Medicine Inc.
NASDAQ:IRON |
Biotechnology | 84.22% |
|
Alpha Tau Medical Ltd
NASDAQ:DRTS |
Biotechnology | 65.79% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
CERo Therapeutics Holdings, Inc. Common Stock Asset Resilience Ratio by Year (None–None)
CERo Therapeutics Holdings, Inc. Common Stock asset resilience ratio by year from None to None. The table below shows the annual Asset Resilience Ratio data for CERo Therapeutics Holdings, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About CERo Therapeutics Holdings, Inc. Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, engages in the development of engineered T cell therapeutics for the treatment of cancer. The company's lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.